Osteoporosis
Red Flags
| Red flag | Why dangerous | Action |
|---|---|---|
| Vertebral fracture + leg weakness / bladder or bowel dysfunction | Spinal cord or cauda equina compression — neurosurgical emergency; mortality without rapid decompression | 999 immediately |
| Bone pain + weight loss + anaemia + elevated ESR + hypercalcaemia | Multiple myeloma — must not be managed as osteoporosis; SPEP, FBC, calcium, renal function urgently | 2WW haematology |
| Atypical femoral fracture (subtrochanteric / mid-shaft) on long-term bisphosphonate | Bisphosphonate-associated atypical fracture — stop bisphosphonate; urgent orthopaedic; bilateral femur X-ray; consider teriparatide | Urgent orthopaedics; stop bisphosphonate |
| Rapidly growing or asymmetric thyroid/neck mass with osteoporosis | Parathyroid carcinoma or thyroid malignancy causing secondary osteoporosis — concurrent 2WW thyroid/endocrine referral | 2WW endocrine / thyroid |
| Fracture in a patient under 50 without clear cause | Unusual — secondary cause must be excluded: hypogonadism, malabsorption, Cushing's, mastocytosis | Full secondary cause screen urgently |
- Not asking about ONJ fear proactively — most common undisclosed concern in osteoporosis
- Not identifying coeliac as secondary cause affecting calcium/vitamin D management
- Not clarifying fracture mechanism (fragility vs trauma) — pivotal clinical decision
999 / Same-Day
Act now- Vertebral fracture + leg weakness / bladder or bowel changeCord/cauda equina compression → 999
- Hip fractureEmergency orthopaedic admission
- Bone pain + weight loss + anaemia + SPEP band2WW haematology (myeloma)
- Atypical femoral fracture on bisphosphonateUrgent orthopaedics; stop bisphosphonate
Treat Within 4 Weeks
Weeks- Fragility fracture (wrist, vertebral, humerus)Pre-treatment bloods + start treatment without DXA delay
- GIOP — new long-term steroid prescriptionStart risedronate + calcium/vitamin D when steroids start
- T-score ≤−2.5 with significant risk factorsPre-treatment bloods → start treatment
Primary Care
GP practice- Osteopenia (T −1 to −2.5) — FRAX-drivenCalculate FRAX; treat if above NOGG threshold; lifestyle if below
- Annual treatment reviewDXA 2-yearly; adherence; bisphosphonate holiday at 5 years
- Falls prevention without fractureLifestyle + supplements + OTAGO programme
- Waiting for DXA before treating a confirmed fragility fracture
- Missing neurological signs with vertebral pain as an emergency trigger
- Not measuring height — the most important single measurement in osteoporosis management
- Not assessing falls risk — falls prevention is co-equal with bone treatment
- Starting bisphosphonate without pre-treatment calcium, eGFR, and vitamin D — prescribing error
- Not checking coeliac-related absorption markers in a patient with known coeliac
"Osteoporosis means that the scaffolding inside your bones has become too thin — like a sponge with too many large holes. It doesn't hurt, which is why it's often called the 'silent disease.' The problem is that when the scaffolding is thin enough, even a small knock or fall can break a bone that wouldn't have broken otherwise — which is what happened with your wrist. We can't fully undo what's there, but we can significantly slow down the loss and actually improve the structure over time. Treatment reduces your risk of another fracture by about half."
"I've read these tablets cause your jaw bone to die."
"I'm really glad you raised that — it's important and I want to give you the proper picture. ONJ is a real but extremely rare side effect. In studies of patients taking weekly alendronate tablets — which is what I'd recommend for you — the risk is less than 1 in 10,000. The risk you've likely read about is much higher with high-dose intravenous bisphosphonates used to treat cancer — that's a completely different situation. To put it in perspective: a hip fracture without treatment in someone with your fracture history carries a roughly 25–30% mortality risk within 12 months. The ONJ risk with your weekly tablet is under 1 in 10,000. I'd also ask you to see your dentist before we start — just as a sensible precaution."
Primary osteoporosis (postmenopausal / age-related)
Most common. DXA T ≤−2.5 or fragility fracture. Alendronate first-line. Calcium + vitamin D mandatory adjunct.
GIOP (glucocorticoid-induced)
Prednisolone ≥7.5 mg for ≥3 months. Risedronate preferred. Start with steroids, not after fracture.
Coeliac disease
Gluten-free diet often improves BMD significantly. Higher vitamin D doses needed. Check absorption markers.
Hypogonadism / premature menopause
HRT or testosterone replacement as primary treatment. Anti-resorptive secondary.
Multiple myeloma
Bone pain + weight loss + anaemia + SPEP band. 2WW haematology. Not osteoporosis.
Vertebral fracture + neurology
Cord/cauda equina compression. 999 emergency.
- Dismissing ONJ concern without risk quantification
- Not using a plain language analogy for osteoporosis mechanism
- Not checking understanding after the explanation
Validate
ONJ fear and medication hesitancy are understandable. Acknowledge explicitly before presenting evidence.
"I completely understand the concern about the tablets — the jaw issue is something many patients have heard about and I want to give you the accurate picture."Explain
ONJ risk <1 in 10,000 with oral weekly tablets. Fracture without treatment: ~25–30% mortality for hip fracture within 12 months. Evidence base and specific risk numbers are essential.
"The risk of jaw problems with the weekly tablet is under 1 in 10,000. A hip fracture without treatment in your situation carries a much greater risk. I want us to make this decision together with the full picture."Negotiate
Dental check as the concrete first step gives patient agency and addresses the concern practically.
"Could we agree on this — see your dentist in the next two weeks, let them know you're starting a bone tablet, then start the alendronate once that's done? I'll also sort the blood tests today."Calcium is the primary mineral in bone hydroxyapatite. Inadequate calcium accelerates bone loss; adequate calcium maximises anti-resorptive efficacy.
~200 mg per dairy portion. If diet provides <700 mg/day, supplement to 1000–1200 mg. Do not exceed 1200 mg — cardiovascular signal above this. Separate from bisphosphonate by 4–6 hours.
Vitamin D is essential for calcium absorption from the gut. Deficiency causes secondary hyperparathyroidism → increased bone resorption. Deficiency dramatically reduces anti-resorptive efficacy and can cause severe hypocalcaemia on starting bisphosphonate.
Combined preparations (Adcal-D3, Calceos) convenient. In coeliac — higher doses often required; check 25-OH level. Must correct before starting anti-resorptive.
Mechanical loading stimulates osteoblast activity. Weight-bearing exercise is the most potent non-pharmacological stimulus for bone maintenance.
Walking, dancing, heel drops (10/day — RCT evidence). Resistance training for appendicular bones. OTAGO programme specifically for falls reduction.
Smoking reduces BMD through osteoblast toxicity. Alcohol >3 units/day is a FRAX risk factor through reduced bone formation and increased falls risk.
Brief alcohol advice: 10 units/week is within guidelines but worth reviewing in context of fracture risk. Smoking cessation referral via NHS Stop Smoking Service.
Falls are the proximate cause of most fragility fractures. Addressing modifiable factors (medications, vision, footwear, home hazards, balance) is complementary to bone treatment.
OTAGO/FaME structured programme. OT home assessment. Medication review (sedatives, hypnotics, antihypertensives). Hip protectors for very high-risk patients.
ONJ risk is dramatically reduced by ensuring good oral health before starting. Dental surgery during bisphosphonate therapy has higher ONJ risk — plan any needed work before starting.
Advise dental review before starting. Inform dentist of bisphosphonate at every dental visit. Excellent oral hygiene throughout. If dental surgery needed: discuss with prescriber — brief holiday evidence equivocal.
Select patient characteristics — see drug cards below
"Take this tablet first thing in the morning on an empty stomach with a full glass of water — then stay upright (sitting or standing) for at least 30 minutes before eating or drinking anything else. Once a week, on the same day each week. Take your calcium and vitamin D supplement at a different time — with lunch or dinner is ideal."
In SCA: alendronate administration counselling (empty stomach + full glass of water + upright 30 min) is a specific Tasks mark. Omitting this = oesophagitis risk = prescribing error. The calcium/vitamin D timing separation (not with alendronate in morning) is also a scoring point.
"Same as alendronate — empty stomach, full glass of water, upright 30 minutes. Once a week on the same day."
In SCA: risedronate is the correct first choice for GIOP. Knowing this specific NICE TA indication gains a Tasks mark.
"A yearly 15-minute drip. You may feel flu-like for a day or two afterwards — that's normal and means the medication is working. The advantage: nothing to take by mouth each week."
"This injection every 6 months is very effective. The most important thing I need to tell you is that you must never stop this injection without speaking to me first — stopping it suddenly can cause multiple fractures to your spine within months. Even if you feel completely well, come back for each 6-month injection. If you can't make the appointment for any reason, contact us immediately."
In SCA: denosumab rebound fracture counselling is one of the most specific and clinically important knowledge points in osteoporosis. Prescribing denosumab without this counselling is an incomplete management — fails a Tasks mark AND potentially an RO mark.
"Once monthly, same date each month, first thing in the morning, full glass of water, upright 60 minutes before eating (longer standing time than weekly tablets)."
"Take this supplement with lunch or dinner — not in the morning with your bone tablet. They need to be taken at different times of day to work properly."
In SCA: omitting calcium + vitamin D co-prescription is a specific Tasks deduction. The TIMING (not with bisphosphonate — 4–6 hrs apart) is also a specific scoring point. Both prescription AND timing must be communicated.
Fear of Falling
Paradoxically, fear of falling after a fracture causes inactivity — which worsens bone density and balance, increasing future fracture risk.
Prescribe physical activity as medicine; refer to structured balance programme. Explain that inactivity is more dangerous than controlled activity.
"The research shows that gentle structured exercise reduces fall risk rather than increasing it — inactivity is actually the bigger danger here."Family Fracture Fear
Patients often fear repeating a parent's outcome — particularly if a parent died or became dependent following a hip fracture. This fear is powerfully motivating if properly engaged.
"You mentioned your mother had a hip fracture — that's exactly why I want us to be proactive. Treatment significantly reduces the chance of that outcome for you."ONJ Anxiety
ONJ fear is the most common psychosocial barrier to treatment acceptance. Requires direct, evidence-based communication — not dismissal. <1/10,000 risk framing plus dental check plan is the most effective approach.
"I'd like you to see your dentist before we start — not because the risk is significant, but because it gives you peace of mind and it's a sensible precaution."Driving and Independence
Wrist and hip fractures often temporarily restrict driving — devastating for patients in rural areas or those with caring responsibilities.
"Has the fracture affected your ability to drive — is that something we should think about alongside the recovery?"Lifelong Medication Concern
Many patients are reluctant to commit to "tablets for life." Frame bisphosphonate holidays (5-year review) early — this significantly improves initial acceptance.
"We would review whether you still need the tablet after 5 years — it's not necessarily a lifetime commitment."Family Screening Implications
A parental hip fracture is a FRAX risk factor for offspring. Screening of adult daughters (after maternal fracture) is recommended.
"It's worth mentioning to your daughters — a parental fracture like yours is a risk factor for them, and they may want to get their bones checked when they reach their 50s."6–8 weeks — Pre-treatment bloods review and treatment initiation
Review calcium, eGFR, vitamin D, FBC, ALP results. If satisfactory: start alendronate 70 mg weekly + calcium/vitamin D. Advise on correct administration. Confirm dental check booked. Begin calcium/vitamin D immediately (do not wait for alendronate start).
3 months — Adherence and tolerability
Is alendronate being taken correctly (empty stomach, upright 30 min)? Any GI side effects? Dental review done? If GI intolerance: switch to risedronate or IV zoledronic acid. Reinforce calcium/vitamin D timing and dose.
1 year — Annual review
Height measurement (document change). Review fracture events. New medications that affect bone? Falls risk reassessment. Vitamin D level (particularly in coeliac). Gluten-free diet adherence reviewed.
2 years — DXA monitoring
Repeat DXA. T-score should stabilise or improve. If worsening despite good adherence: review secondary causes, absorption (calcium/vitamin D), and consider step-up therapy. If significant improvement: reinforce adherence; continue current regimen.
5 years — Bisphosphonate holiday decision
Review: current T-score, fracture history on treatment. If T-score improved + fracture-free + low-moderate risk: holiday (2–3 years) with annual review. If high-risk (T <−2.5 hip, previous hip/vertebral fracture): continue further 5 years or step up to denosumab.
⚠ Three scenario-specific safety-net phrases
- Alendronate without administration counselling — prescribing error (oesophagitis)
- Calcium and vitamin D not co-prescribed — mandatory omission
- ONJ concern not addressed with risk quantification
- Denosumab rebound not counselled if denosumab prescribed
- No pre-treatment bloods plan
- No neurological safety-net
- Closing question absent
- Pre-treatment bloods: calcium, eGFR, vitamin D named
- Alendronate 70 mg weekly with full administration counselling
- Calcium + vitamin D co-prescribed with timing (not with bisphosphonate)
- ONJ: <1/10,000 + dental check before starting
- Denosumab rebound counselling if applicable
- Neurological safety-net: vertebral fracture + neurology = 999
- Follow-up: 6–8 week bloods review + 3-month adherence check
- ONJ concern proactively explored and addressed (not just if raised)
- Scaffolding analogy used for plain language explanation
- Family hip fracture fear acknowledged and treatment framed as independence-preserving
- Dental check negotiated as concrete first step
- Understanding checked
- Closing question asked
Who you are
Carol White, 58 years old, part-time administrator. Colles' wrist fracture 3 weeks ago after tripping on a flat pavement (minor trip, level ground — fragility fracture). Postmenopausal since age 51. History of coeliac disease 8 years ago — mostly gluten-free but admits to lapses at family events. No calcium or vitamin D supplements ("nobody told me to take them"). Non-smoker. 10 units alcohol/week. BMI 23. No other medications. Mother had a hip fracture aged 70 and spent her last years in a care home — Carol is frightened of the same outcome.
Hidden agenda
Has read online that bisphosphonates cause "jaw bone death." Will not agree to take tablets unless this concern is specifically addressed with risk quantification — not just "it's rare." She needs to hear the <1 in 10,000 risk with weekly tablets AND the distinction from cancer IV doses. If this is addressed well, she relaxes significantly and asks about the dental check. If dismissed ("it's nothing to worry about"), she leaves without accepting treatment. The dental check offer is the key turning point — it gives her agency.
Coeliac history if asked
- Diagnosed 8 years ago; mostly gluten-free but slips occasionally
- No calcium or vitamin D supplements — "nobody told me to take them"
- No recent blood tests including vitamin D
Bonus details
- If asked about falls: "I just tripped — I'm not a 'faller,' I just had bad luck."
- If told about dental check: "Oh — that's actually quite sensible. I can do that."
- Mother's hip fracture: "She never really walked properly again. She died in a care home."
Resolution criteria: Carol accepts treatment if: (1) ONJ addressed with <1/10,000 risk framing + distinction from cancer doses; (2) dental check offered as concrete precaution; (3) coeliac-related deficiency explained + supplements prescribed; (4) alendronate administration counselled correctly; (5) mother's hip fracture fear acknowledged + treatment framed as independence-preserving.
→ Always: <1/10,000 with weekly tablets; distinguish from cancer IV doses
→ Mandatory with every anti-resorptive; both elements required
→ Empty stomach + full glass water + upright 30 min — all three required
→ Mandatory safety check before prescribing any anti-resorptive
→ "I can see from your notes…" gains GS mark and saves time
→ Most important single measurement; ≥4cm → spinal X-ray
→ Counsel before prescribing: never stop suddenly — rebound fracture risk
→ T-score alone does not make treatment decision in osteopenia
→ Always end with "Is there anything else on your mind?"